|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||131.75 - 133.83|
|52-week range||121.00 - 148.99|
|Beta (3Y monthly)||0.76|
|PE ratio (TTM)||24.56|
|Earnings date||15 Oct 2019|
|Forward dividend & yield||3.80 (2.82%)|
|1y target est||149.17|
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at firstname.lastname@example.orgTo contact the editor responsible for this story: Drew Armstrong at email@example.comFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Johnson & Johnson vowed to defend itself against lawsuits alleging the company fueled the opioid crisis and that its namesake talc-based baby powder caused ovarian cancer and mesothelioma.
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
Shares of Goldman Sachs Group Inc. surged 2.3% in morning trading after big second-quarter profit and revenue beats, with the price gain enough to keep the Dow Jones Industrial Average in positive territory. The stock rose $4.88, which would add about 33 points to the Dow's price, which is up 7 points. For the other Dow earnings reporters, J.P. Morgan Chase & Co.'s stock slipped 41 cents, or 0.4%, and Johnson & Johnson shares gave up $1.60, or 1.2%; combined, those declines would shave about 14 points off the Dow's price.
Stocks got off to a slightly lower start Tuesday as investors digested a stream of earnings reports, including results from Dow components Johnson & Johnson and Goldman Sachs Group Inc. . The Dow Jones Industrial Average fell around 7 points, or less than 0.1%, to 27,352, while the S&P 500 was off 0.1% at 3,011.12. The Nasdaq Composite fell 0.1% to 8,245.28. All three major indexes eked out record finished in subdued trading on Monday. Shares of Goldman Sachs were up 0.9%, while Johnson & Johnson shares fell 1.7%. Both companies topped earnings forecasts.
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.61% and 1.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
While J&J's pharmaceuticals unit has in recent years cushioned the impact of relatively slow growth in the company's medical device and consumer units, some of its older drugs have been hurt by competition from cheaper copies. "We expect the largest impacts from generics and biosimilars for the year in our pharmaceutical business to occur in the third quarter," Chief Financial Officer Joseph Wolk said on a conference call. Sales of prostate cancer treatment Zytiga fell 23% in the quarter, hurt by generic copies, and sales of J&J's blockbuster arthritis drug Remicade fell 16%, impacted by biosimilar rivals.
Investing.com - Johnson & Johnson (NYSE:JNJ) lifted its annual sales outlook for the year after reporting second-quarter earnings that beat consensus on the top and bottom line.
U.S. stock futures point to a mixed open after a day of small gains kept the record closes going on Wall Street.
Shares of Johnson & Johnson rose 0.8% in premarket trade Tuesday after the health-products giant reported second-quarter earnings and revenue that beat Wall Street expectations. Profit for the latest quarter rose to $5.607 billion, or $2.08 per share, from $3.954 billion, or $1.45 per share, a year ago. Adjusted EPS was $2.58 per share, beating the FactSet consensus of $2.46 per share. Revenue fell to $20.562 billion from $20.830 billion in the year-earlier quarter, but beat the FactSet consensus of $20.293 billion. Sales from J&J's consumer business rose to $3.544 billion from $3.504 billion a year ago, while the company's pharmaceuticals segment brought in $10.529 billion, up from $10.354 billion a year ago. J&J's medical devices business brought in $6.489 billion, down from $6.972 billion a year ago. J&J boosted its 2019 sales outlook to between $80.8 billion and $81.6 billion from between $80.4 billion and $81.2 billion. The company also reaffirmed its full-year adjusted EPS of between $8.53 and $8.63 per share. Shares of J&J have gained 4.4% in the year to date, while the Dow Jones Industrial Average has gained 17.3% and the S&P 500 has gained 20.2%.
Johnson & Johnson's profit jumped 42% in the second quarter, with all three of the sprawling health-care company's businesses performing better than Wall Street expected.
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fuelling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis. Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks. Brad Beckworth, a lawyer for the state, said J&J knew opioids were harmful, yet minimized the risk of addiction in their marketing, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.